1.蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233000
2.蚌埠医学院药学院,安徽 蚌埠 233000
3.安徽省生物化学药物工程研究中心,安徽 蚌埠 233000
邢瑞丽,第一作者,硕士生,研究方向:妇科肿瘤,E-mail: xingruili618@163.com
印天,硕士生,共同第一作者,研究方向:妇科肿瘤,E-mail: yintian415316@163.com;
纸质出版日期:2023-03-20,
收稿日期:2022-10-28,
扫 描 看 全 文
邢瑞丽,印天,范方田等.RBMS3表达与上皮性卵巢癌临床病理特征及预后[J].中山大学学报(医学科学版),2023,44(02):277-285.
XING Rui-li,YIN Tian,FAN Fang-tian,et al.RBMS3 Expression and Its Correlation with Clinicopathological Features and Prognosis of Epithelial Ovarian Cancer[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(02):277-285.
邢瑞丽,印天,范方田等.RBMS3表达与上皮性卵巢癌临床病理特征及预后[J].中山大学学报(医学科学版),2023,44(02):277-285. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0212.
XING Rui-li,YIN Tian,FAN Fang-tian,et al.RBMS3 Expression and Its Correlation with Clinicopathological Features and Prognosis of Epithelial Ovarian Cancer[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(02):277-285. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0212.
目的
2
探讨RNA结合基序单链相互作用蛋白3(RBMS3)在上皮性卵巢癌(EOC)组织中的表达,及其与EOC组织的临床病理特征和预后的关系。
方法
2
选取蚌埠医学院第一附属医院2015年1月~2019年12月经术后病理证实的110例EOC石蜡包埋组织及73例上皮性卵巢良性肿瘤石蜡包埋组织,利用抗RBMS3的多克隆抗体进行免疫组织化学染色(IHC),检测各组织中RBMS3的表达情况,并分析RBMS3的表达与EOC临床病理参数及预后的相关性。
结果
2
在EOC组织与上皮性卵巢良性肿瘤组织中RBMS3均表达,而RBMS3在EOC组织中的表达水平明显低于其在上皮性卵巢良性肿瘤组织中的表达水平(
P
<
0.05);在EOC组织中的表达水平与其国际妇产科联合会的分期(FIGO分期)、组织学分级、CEA水平及生存状况有关(
P
<
0.05);Kaplan-Meier生存曲线表明:RBMS3的低表达与EOC患者的无疾病进展期(PFS)和总生存期(OS)的降低均有关(
P
<
0.05);单因素分析结果示:RBMS3表达、FIGO分期、残余病灶大小、肠道转移、腹腔种植与EOC患者的OS相关(
P
<
0.05);多因素分析示:RBMS3低表达及肠道转移是EOC患者预后不良的独立危险因素(
P
<
0.05)。
结论
2
RBMS3在EOC组织中低表达,且与EOC患者的不良预后密切相关。因此,RBMS3可能在EOC组织中发挥抑癌基因作用,且RBMS3是一种有用的EOC独立预后标记物,可能为EOC的靶向治疗提供一种潜在靶点。
Objective
2
To investigate the expression of RNA binding motif single stranded interacting protein 3 (RBMS3) in epithelial ovarian cancer (EOC) tissues and its relationship with the clinicopathological features and prognosis of EOC.
Methods
2
The study enrolled the paraffin-embedded tissues from 110 EOC cases and 73 benign epithelial ovarian tumor cases pathologically diagnosed in the first affiliated Hospital of Bengbu Medical College from January 2015 to December 2019. By using anti-RBMS3 polyclonal antibody, the immunohistochemical staining was employed to detect RBMS3 expression in the tissues and then its correlation with the clinicopathological parameters and prognosis of EOC was analyzed.
Results
2
RBMS3 was expressed in both EOC and benign epithelial ovarian tumor tissues. RBMS3 expression in EOC tissues, significantly related with International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, CEA levels and survival status, was significantly lower than that in benign epithelial ovarian tumor tissues (
P
<
0.05). Kaplan–Meier survival curve showed that low RBMS3 expression in EOC patients was correlated with decreased progression-free survival (PFS) and overall survival (OS) (
P
<
0.05). Univariate analysis showed that RBMS3 expression, FIGO stage, residual lesion size, intestinal metastasis and intraperitoneal implantation were associated with OS of EOC patients (
P
<
0.05); multivariate analysis showed that low RBMS3 expression and intestinal metastasis were independent risk factors for poor prognosis in EOC patients (
P
<
0.05).
Conclusions
2
RBMS3 is expressed at low levels in EOC tissues, which is closely related to poor prognosis of EOC patients. RBMS3 may function as a tumor suppressor gene in EOC tissues and can be used as an EOC-independent prognostic marker for targeted therapy against EOC
.
上皮性卵巢癌RBMS3临床病理特征预后
epithelial ovarian cancer (EOC)RNA binding motif single stranded interacting protein 3 (RBMS3)clinicopathological featuresprognosis
Alyahri N, Abdi S, Khan W, et al. Novel associations between BRCA1 variants C.181 T>G (Rs28897672) and ovarian crisk in saudi females[J]. J Med Biochem, 2019, 38(1): 13-21.
张玉娟, 张梦, 王晴, 等. APOBEC-1和NF-1在上皮性卵巢癌的作用机制及临床意义[J]. 遵义医科大学学报, 2021, 44(2): 188-193.
Zhang YJ, Zhang M, Wang Q, et al. Mechanism and clinical significance of APOBEC-1 and NF-1 in epithelial ovarian cancer[J]. J Zunyi Med Univ, 2021, 44(2): 188-193.
Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery[J]. J Turk Ger Gynecol Assoc, 2019, 20(1): 47-54.
Si W, Kang S, Sun H, et al. Genetic polymorphisms in hMSH2 and hMLH1 genes are associated with prognosis in epithelial ovarian cancer patients[J]. Int J Gynecol Cancer, 2019, 29(7): 1148-55.
卵巢癌最新指南与共识[J]. 重庆医科大学学报, 2021, 46(6): 630; +731.
Latest guidelines and consensus on ovarian cancer[J]. J Chongqing Med Univ, 2021, 46(6): 630; +731.
Deng Y, Liu L, Feng W, Lin Z, et al. High expression of MYL9 indicates poor clinical prognosis of epithelial ovarian cancer[J]. Recent Pat Anticancer Drug Discov, 2021, 16(4): 533-539.
Liu L, Zeng Z, Yi J, et al. Expression and clinical significance of transcription factor 4 (TCF4) in epithelial ovarian cancer[J]. Cancer Biomark, 2019, 24(2): 213-221.
Perez-Juarez CE, Arechavaleta-Velasco F, Zeferino-Toquero M, et al. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors[J]. Med Oncol, 2019, 37(1): 4.
Yao Y, Liu L, He W, et al. Low expression of KIF7 indicates poor prognosis in epithelial ovarian cancer[J]. Cancer Biomark, 2019, 26(4): 481-489.
Xu M, Jin T, Chen L, et al. Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma[J]. Gene, 2019, 696: 63-71.
Liu L, Yi J, Deng X, et al. MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer[J]. Oncol Lett, 2019, 18(2): 1049-56.
Bonifácio VDB. Ovarian cancer biomarkers: moving forward in early detection[J]. Adv Exp Med Biol, 2020, 1219: 355-363.
Zhang M, Cheng S, Jin Y, et al. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188503.
Hong H, Zhu H, Zhao S, et al. The novel circCLK3/miR-320a/FoxM1 axis promotes cervical cancer progression[J]. Cell Death Dis, 2019, 10(12): 950.
Wu Y, Yun D, Zhao Y, et al. Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer[J]. Oncotarget, 2017, 8(1): 1262-1277.
Wu Y, Meng D, You Y, et al. Increased expression of RBMS3 predicts a favorable prognosis in human gallbladder carcinoma[J]. Oncol Rep, 2020, 44(1): 55-68.
Zhu L, Xi PW, Li XX, et al. The RNA binding protein RBMS3 inhibits the metastasis of breast cancer by regulating Twist1 expression[J]. J Exp Clin Cancer Res, 2019, 38(1): 105.
Wang C, Wu Y, Liu Y, et al. Tumor suppressor effect of RBMS3 in breast cancer[J]. Technol Cancer Res Treat, 2021, 20: 15330338211004921.
Sun X, Zhang W, Li H, et al. Stonin 2 overexpression is correlated with unfavorable prognosis and tumor invasion in epithelial ovarian cancer[J]. Int J Mol Sci, 2017, 18(8): 1653.
Beiersdorf J, Scheungraber C, Wunsch K, et al. Combined assessment of 3q26 amplification and promoter methylation in patients with high grade cervical lesions show age specific differences[J]. Genes Chromosomes Cancer, 2020, 59(3): 168-177.
Dong S, Ma M, Li M, et al. LncRNA MEG3 regulates breast cancer proliferation and apoptosis through miR-141-3p/RBMS3 axis[J]. Genomics, 2021, 113(4): 1689-1704.
Wang JJ, Liu XY, Du W, et al. RBMS3 delays disc degeneration by inhibiting Wnt/β-catenin signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(2): 499-507.
徐惠绵, 王鑫. 我国胃癌诊治临床研究现状与展望[J]. 中华胃肠外科杂志, 2020, 23(2): 109-114.
Xu HM, Wang X. Current status and outlook of clinical research on the diagnosis and treatment of gastric cancer in China[J]. Chin J Gastrointest Surg, 2020, 23(2): 109-114.
Wu G, Cao L, Zhu J, et al. Loss of RBMS3 confers platinum resistance in epithelial ovarian cancer via activation of miR-126-5p/β-catenin/CBP signaling[J]. Clin Cancer Res, 2019, 25(3): 1022-1035.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构